HRS-6208 combined with HRS-8080, fulvestrant, or letrozole (± HRS-6209) for advanced metastatic breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1/2, multicenter trial in China tests multiple combination regimens built around the investigational agent HRS-6208, administered with HRS-8080, fulvestrant, or letrozole, and optionally with HRS-6209. The study uses dose-escalation and expansion cohorts to characterize safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Eligible participants are adult women with advanced unresectable or metastatic breast cancer and adequate organ function, treated at participating hospital sites. Key outcomes include adverse events, recommended phase 2 dose(s), pharmacokinetic profiles, and measures of tumor response or disease control.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Female, aged 18-75 (inclusive);
2. ECOG score 0-1;
3. Estimated survival time ≥ 12 weeks;
4. Possessing adequate bone marrow and organ function;
5. Participants of reproductive/childbearing potential must agree to take adequate and effective contraceptive measures from the time they sign the informed consent form, during the study treatment period, and up to 2 years after the last use of the trial medication;
6. Participants must provide informed consent for this study before the trial and voluntarily sign a written informed consent form.

Exclusion Criteria:

1. Within 5 years prior to the first dose of study medication, the occurrence of other malignancies, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, and post-radical surgery thyroid papillary carcinoma;
2. Active brain metastasis, carcinomatous meningitis, spinal cord compression, or history of primary central nervous system tumors;
3. Severe bone damage caused by tumor bone metastasis as determined by the investigator;
4. Adverse events caused by previous anti-tumor treatment have not been resolved;
5. Participants with one of multiple factors affecting oral medication;
6. History of severe cardiovascular and cerebrovascular diseases;
7. Presence of severe infections;
8. Significant clinically meaningful bleeding within 3 months prior to the first dose of study medication;
9. Active autoimmune diseases, history of immune deficiency, history of autoimmune diseases, or history of diseases or syndromes requiring systemic steroid hormone or immunosuppressive drug treatment, or acquired conditions (HIV infection), congenital immune deficiency diseases, or history of organ transplantation;
10. Active untreated hepatitis;
11. History of active tuberculosis infection within 1 year prior to enrollment, or history of active tuberculosis infection more than 1 year ago without standard treatment;
12. Washout period of prior drug or treatment did not meet protocol requirements before the first dose of study medication;
13. Prior use of prohibited drugs specified in the protocol;
14. Is pregnant or breastfeeding or planning to become pregnant within 2 years after the last dose of study medication;
15. History of clear neurological or psychiatric disorders, and participants with a history of psychiatric drug abuse or drug addiction;
16. Allergic reactions to any study drug or excipients;
17. Factors confirmed by the investigator as unsuitable for participation in this clinical study.

Where it's running

• The Second Affiliated Hospital of Dalian Medical University
  Dalian, Liaoning, China Recruiting
• West China Hospital, Sichuan University
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Yunxia Feng
• Email: yunxia.feng.yf29@hengrui.com
• Phone: +86-0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing new drug combinations for advanced breast cancer

  This study is testing different combinations of drugs, including HRS-2189 and Fluvastatin, to see if they can help people with advanced breast cancer feel better and manage their disease.

  Recruiting at 2 sites Phase 1/2 Shandong Suncadia Medicine Co., Ltd. · Harbin, Heilongjiang and 1 other locations · NCT06679036

• Evaluating HRS-6209 with other treatments for advanced breast cancer

  This study is testing a new drug called HRS-6209 combined with other treatments to see if it helps women with advanced breast cancer that hasn’t responded to previous therapies.

  Recruiting Phase 1/2 Jiangsu HengRui Medicine Co., Ltd. · Shanghai, Shanghai Municipality · NCT06555068

• SKB264 with inetetamab for HER2-positive advanced breast cancer after progression on T-DXd

  This trial will see if combining SKB264 and inetetamab helps adults with HER2-positive unresectable or metastatic breast cancer whose disease progressed after trastuzumab deruxtecan (T-DXd).

  Recruiting Phase 2 Fudan University · Shanghai · NCT07182721

• HER3-DXd and T-DXd combo therapy in HR-positive, HER2-low/ultralow breast cancer

  This trial tests a combination of patritumab deruxtecan and trastuzumab deruxtecan in people with HR-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer to see if it is safe and shows anti-tumor activity.

  Recruiting at 7 sites Phase 1/2 Daiichi Sankyo · Los Angeles, California and 71 other locations · NCT07701941

• Combination therapy for advanced breast cancer

  This study is testing a new combination of medications to see if it can help women with advanced breast cancer feel better and improve their treatment outcomes.

  Recruiting at 2 sites Phase 1/2 Shandong Suncadia Medicine Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT06167694

• Trastuzumab Rezetecan versus Trastuzumab Deruxtecan for unresectable HER2‑low, HR‑positive breast cancer

  This Phase 2 trial tests different doses of Trastuzumab Rezetecan compared with Trastuzumab Deruxtecan in women with HR-positive, HER2-low unresectable locally recurrent or metastatic breast cancer to see which dose is safer and more effective.

  Recruiting Phase 2 Jiangsu HengRui Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT07497386

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.